MedTrace Logo

Mass Spectrometry in Single Bladder Cancer Cells

NCT03639090 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2020-10-19

No results posted yet for this study

Summary

The study is a pilot study in the feasibility of a diagnostic technique. There is no current data on detection of cisplatin in cancer cells derived from human urine. This study will generate preliminary data so that future studies may be done with more definitive end points in mind.

Conditions

Interventions

DIAGNOSTIC_TEST

mass spectrometry

mass spectrometry for bladder cancer cells

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Jonathan Heinlen, M.D. · University of Oklahoma HSC, Department of Urology

Eligibility

Min Age
30 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2020-10-08
Completion
2020-10-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03639090 on ClinicalTrials.gov